• Je něco špatně v tomto záznamu ?

Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma

G. Gakis, TM. Morgan, S. Daneshmand, KA. Keegan, T. Todenhöfer, J. Mischinger, T. Schubert, HB. Zaid, J. Hrbacek, B. Ali-El-Dein, RH. Clayman, S. Galland, K. Olugbade, M. Rink, HM. Fritsche, M. Burger, SS. Chang, M. Babjuk, GN. Thalmann, A....

. 2015 ; 26 (8) : 1754-9. [pub] 20150512

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020810

BACKGROUND: To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma (PUC). PATIENTS AND METHODS: A series of 124 patients (86 men, 38 women) were diagnosed with and underwent surgery for PUC in 10 referral centers between 1993 and 2012. Kaplan-Meier analysis with log-rank testing was used to investigate the impact of perioperative chemo(radio)therapy on overall survival (OS). The median follow-up was 21 months (mean: 32 months; interquartile range: 5-48). RESULTS: Neoadjuvant chemotherapy (NAC), neoadjuvant chemoradiotherapy (N-CRT) plus adjuvant chemotherapy (ACH), and ACH was delivered in 12 (31%), 6 (15%) and 21 (54%) of these patients, respectively. Receipt of NAC/N-CRT was associated with clinically node-positive disease (cN+; P = 0.033) and lower utilization of cystectomy at surgery (P = 0.015). The objective response rate to NAC and N-CRT was 25% and 33%, respectively. The 3-year OS for patients with objective response to neoadjuvant treatment (complete/partial response) was 100% and 58.3% for those with stable or progressive disease (P = 0.30). Of the 26 patients staged ≥cT3 and/or cN+ disease, 16 (62%) received perioperative chemo(radio)therapy and 10 upfront surgery without perioperative chemotherapy (38%). The 3-year OS for this locally advanced subset of patients (≥cT3 and/or cN+) who received NAC (N = 5), N-CRT (N = 3), surgery-only (N = 10) and surgery plus ACH (N = 8) was 100%, 100%, 50% and 20%, respectively (P = 0.016). Among these 26 patients, receipt of neoadjuvant treatment was significantly associated with improved 3-year relapse-free survival (RFS) (P = 0.022) and OS (P = 0.022). Proximal tumor location correlated with inferior 3-year RFS and OS (P = 0.056/0.005). CONCLUSION: In this series, patients who received NAC/N-CRT for cT3 and/or cN+ PUC appeared to demonstrate improved survival compared with those who underwent upfront surgery with or without ACH.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020810
003      
CZ-PrNML
005      
20160725112412.0
007      
ta
008      
160722s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdv230 $2 doi
024    7_
$a 10.1093/annonc/mdv230 $2 doi
035    __
$a (PubMed)25969370
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gakis, G $u Department of Urology, University of Tuebingen, Tuebingen, Germany georgios.gakis@googlemail.com.
245    10
$a Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma / $c G. Gakis, TM. Morgan, S. Daneshmand, KA. Keegan, T. Todenhöfer, J. Mischinger, T. Schubert, HB. Zaid, J. Hrbacek, B. Ali-El-Dein, RH. Clayman, S. Galland, K. Olugbade, M. Rink, HM. Fritsche, M. Burger, SS. Chang, M. Babjuk, GN. Thalmann, A. Stenzl, JA. Efstathiou,
520    9_
$a BACKGROUND: To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma (PUC). PATIENTS AND METHODS: A series of 124 patients (86 men, 38 women) were diagnosed with and underwent surgery for PUC in 10 referral centers between 1993 and 2012. Kaplan-Meier analysis with log-rank testing was used to investigate the impact of perioperative chemo(radio)therapy on overall survival (OS). The median follow-up was 21 months (mean: 32 months; interquartile range: 5-48). RESULTS: Neoadjuvant chemotherapy (NAC), neoadjuvant chemoradiotherapy (N-CRT) plus adjuvant chemotherapy (ACH), and ACH was delivered in 12 (31%), 6 (15%) and 21 (54%) of these patients, respectively. Receipt of NAC/N-CRT was associated with clinically node-positive disease (cN+; P = 0.033) and lower utilization of cystectomy at surgery (P = 0.015). The objective response rate to NAC and N-CRT was 25% and 33%, respectively. The 3-year OS for patients with objective response to neoadjuvant treatment (complete/partial response) was 100% and 58.3% for those with stable or progressive disease (P = 0.30). Of the 26 patients staged ≥cT3 and/or cN+ disease, 16 (62%) received perioperative chemo(radio)therapy and 10 upfront surgery without perioperative chemotherapy (38%). The 3-year OS for this locally advanced subset of patients (≥cT3 and/or cN+) who received NAC (N = 5), N-CRT (N = 3), surgery-only (N = 10) and surgery plus ACH (N = 8) was 100%, 100%, 50% and 20%, respectively (P = 0.016). Among these 26 patients, receipt of neoadjuvant treatment was significantly associated with improved 3-year relapse-free survival (RFS) (P = 0.022) and OS (P = 0.022). Proximal tumor location correlated with inferior 3-year RFS and OS (P = 0.056/0.005). CONCLUSION: In this series, patients who received NAC/N-CRT for cT3 and/or cN+ PUC appeared to demonstrate improved survival compared with those who underwent upfront surgery with or without ACH.
650    _2
$a adenokarcinom $x mortalita $x terapie $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a paklitaxel vázaný na albumin $x aplikace a dávkování $7 D000068196
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a karboplatina $x aplikace a dávkování $7 D016190
650    _2
$a spinocelulární karcinom $x mortalita $x terapie $7 D002294
650    _2
$a karcinom z přechodných buněk $x mortalita $x terapie $7 D002295
650    _2
$a chemoradioterapie $x metody $7 D059248
650    _2
$a adjuvantní chemoterapie $x metody $7 D017024
650    _2
$a cisplatina $x aplikace a dávkování $7 D002945
650    _2
$a cystektomie $7 D015653
650    _2
$a deoxycytidin $x aplikace a dávkování $x analogy a deriváty $7 D003841
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorouracil $x aplikace a dávkování $7 D005472
650    _2
$a lidé $7 D006801
650    _2
$a ifosfamid $x aplikace a dávkování $7 D007069
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mitomycin $x aplikace a dávkování $7 D016685
650    _2
$a neoadjuvantní terapie $x metody $7 D020360
650    _2
$a paclitaxel $x aplikace a dávkování $7 D017239
650    _2
$a perioperační péče $7 D019990
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a uretra $x chirurgie $7 D014521
650    _2
$a nádory močové trubice $x mortalita $x terapie $7 D014523
650    _2
$a diverze moči $7 D014547
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Morgan, T M $u Department of Urology, University of Michigan, Ann Arbor, USA.
700    1_
$a Daneshmand, S $u Institute of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles.
700    1_
$a Keegan, K A $u Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, USA.
700    1_
$a Todenhöfer, T $u Department of Urology, University of Tuebingen, Tuebingen, Germany.
700    1_
$a Mischinger, J $u Department of Urology, University of Tuebingen, Tuebingen, Germany.
700    1_
$a Schubert, T $u Department of Urology, University of Tuebingen, Tuebingen, Germany.
700    1_
$a Zaid, H B $u Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, USA.
700    1_
$a Hrbacek, J $u 2nd Medical School, Department of Urology, Charles University, Prague, Czech Republic.
700    1_
$a Ali-El-Dein, B $u Urology and Nephrology Center, Mansoura Clinic, Mansoura, Egypt. $7 gn_A_00004228
700    1_
$a Clayman, R H $u Department of Radiooncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
700    1_
$a Galland, S $u Department of Radiooncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
700    1_
$a Olugbade, K $u Department of Urology, University of Michigan, Ann Arbor, USA.
700    1_
$a Rink, M $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg.
700    1_
$a Fritsche, H-M $u Department of Urology, University Hospital Regensburg, Regensburg, Germany.
700    1_
$a Burger, M $u Department of Urology, University Hospital Regensburg, Regensburg, Germany.
700    1_
$a Chang, S S $u Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, USA.
700    1_
$a Babjuk, M $u 2nd Medical School, Department of Urology, Charles University, Prague, Czech Republic.
700    1_
$a Thalmann, G N $u Department of Urology, University Hospital Bern, Bern, Switzerland.
700    1_
$a Stenzl, A $u Department of Urology, University of Tuebingen, Tuebingen, Germany.
700    1_
$a Efstathiou, J A $u Department of Radiooncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
773    0_
$w MED00000432 $t Annals of oncology official journal of the European Society for Medical Oncology ESMO $x 1569-8041 $g Roč. 26, č. 8 (2015), s. 1754-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25969370 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160725112630 $b ABA008
999    __
$a ok $b bmc $g 1155480 $s 945338
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 26 $c 8 $d 1754-9 $e 20150512 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace